{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"description":"The safety population will consist of all participants who receive any amount of study treatment. Safety will be assessed by evaluation of AEs using the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Specific AEs will be counted once for each participant for calculating rates but will be presented in total in participant listings including frequency of non-hematologic grade 3 or higher adverse events.","groups":[{"description":"Participants received pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Treatment (Pembrolizumab)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Up to 30 days after discontinuing study treatment, approximately 1 year and 8 months","title":"Proportion of Participants With Reported Treatment-related Adverse Events","type":"SECONDARY","unitOfMeasure":"Participants"}